0

Makoto TANIHARA

ICS Convention Design, Inc.

February 2013

Asia’s Premier Partnering Event for the Biotechnology Industry

1

Event Outline

<Photo highlights 2012>

Japan Pharmaceutical Manufacturers Association

Japan Bioindustry Association

BioJapan 2013 -World Business Forum- Date: October 9 (Wed.)- 11 (Fri.), 2013

Venue: Pacifico YOKOHAMA *YOKOHAMA is a port city in Kanagawa prefecture just 30 minutes away from the center of Tokyo

Organizer: ・BioJapan Organizing Committee including,

・ICS Convention Design, Inc.

Overview

About BioJapan

BioJapan provides you an opportunity to meet with 700+

biotech and life science companies in Yokohama. Business

development teams from almost all global and Japanese

pharma companies will gather in Yokohama for the 15th

BioJapan. The 2013 event will consist of Partnering, Exhibition

and Seminars.

Synergy

Exhibition Seminars

Partnering

Overview

2

Keynote Speech

Organizer’s Seminars

Luncheon Seminars

Sponsored Seminars

BioJapan 2013 Floor Layout *Subject to change

Annex Hall Exhibition Hall *Partnering Area, Exhibition and Seminars /10,000㎡

40 Sessions in Total with

5,000+ audiences!

Exhibitor’s Presentations

Academic Seeds Presentations

100+ Sessions on

Up-to-date Seeds!

Global Partnering Seminar

Pacifico Yokohama

*Seminars

Overview

3

BioJapan 2012 highlights

Partnering：

･541 companies / 868 delegates from 22 countries

･3,372 one-to-one meetings

Exhibition：

･434 exhibitors / 351 booth stands from 18 countries

･12,369 visitors from 27 countries

Seminars:

･21 Organizer's seminars

･18 Sponsored seminars

･112 Company presentations

Overview

4

Japanese Pharma

Partnering Participating Companies at BioJapan 2012

*Almost all Japanese pharma companies participated in 2012.

Bio Cluster in Japan

*Approx. 150 Japanese biotech companies participated in 2012.

Ajinomoto, Astellas, Chugai Pharmaceutical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Eisai, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Meiji Seika Pharma, Mochida Pharmaceutical, Nippon Kayaku, Nippon Shinyaku, Ono Pharmaceutical, Otsuka Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takara Bio, Taisho Pharmaceutical. Takeda, Teijin Pharma, Zeria Pharmaceutical and others.

Kurume Cutting-egde Medical Research Center, Metropolitan Bio Network, Northern Advancement Center for Science & Technology, Osaka Bio Headquarter, Hokuriku Industrial Advancement Center and others.

5

6

Participating Companies at BioJapan 2012

DuPont, Fujifilm Corporation, Kaneka, Kao Corporation, Mitsubishi Chemical Corporation, Roche Diagnostics, Shiseido, Sumitomo Chemical, Teijin Group, Toray and others.

Keio University, Kyoto University, Osaka University, Tokyo Institute of Technology, Tsukuba University, University of Tokyo and others.

Partnering

AIST- National Institute of Advanced Industrial Science and Technology, JST- Japan Science and Technology Agency, Organization for Small & Medium Enterprises and Regional Innovation, RIKEN and others

Global Pharma (without Japanese pharma)

AstraZeneca, Baxter, Bristol-Myers Squibb, Eli Lilly (Japan), F. Hoffmann-La Roche, GlaxoSmithKline, Janssen Pharma, MSD, (Nippon) Boehringer Ingelheim, Novartis, Pfizer and Sanofi.

Other companies

Governmental Agencies

Academics

Online Partnering System

The BioJapan matching system is available and the

system will enable you to pre-arrange meetings prior

to the event. Create new partnerships and strengthen

existing business relationships using the system!

Partnering

<Before the event> <At the BioJapan>

The 2013 BioJapan partnering is expected to attract

700+ companies. 7

Registration fee

Your registration fee covers:

･Access to the BioJapan matching (partnering) system

･Access to the exhibition & annex hall and partnering area

･Lunch for all 3 days at the partnering area

･Wednesday Welcome Reception

･Thursday Partnering Party

Registration fee: JPY50,000 (taxes included) per person

*EUR400.00 (Based on EUR1.00=JPY125.00) or USD555.00 (Based on USD1.00=JPY90.00)

Partnering

(NEW) 14-minute presentation in the exhibition hall will be available at the extra

fee of JPY105,000 (EUR840.00 or USD1,150.00). 8

Specific Theme Zones in 2012

-Alliance zone (for Pharmaceutical Companies)

-Regenerative Medicine Zone

-Drug Development Services Zone

-In-Silico Drug Discovery Zone

General information Exhibition

Opportunity to promote your products and services to

qualified participants, especially to participants from

pharmaceutical companies!

Exhibition Categories

-Drug and Drug discovery (Small-molecule drug, biologics and vaccine etc.)

-Drug Discovery support and contract services (Drug synthesis services, Analysis contract services

and Chemical compound libraries and screening etc.)

-Medical treatment, Diagnosis and Medical devices and equipments (Biomarkers and Gene therapy etc.)

-Research Devices, Reagents and Facilities (Research Devices, Bioinformatics and Bioimaging etc.)

-Others (Functional Food, Agriculture, Bio-cluster, Universities and Government Agencies etc.)

9

Exhibition Fees and Exhibitor Benefits Exhibition

Exhibitor Benefits:

1) Partnering account(s) will be provided

according to your booth space.

2) Company name listed in the BioJapan

2013 official guidebook

3) Company Directory listing on

BioJapan 2013 website

Exhibition Fees:

・Booth space per 9 sqm:

Early bird: JPY420,000 *EUR3,360

Regular: JPY472,500 *EUR3,780

･9 sqm Shell Scheme Booth

Early bird based: JPY525,000 *EUR4,200

･4 sqm Shell Scheme Booth: JPY199,500 *EUR1,600

<Bavarian pavilion at BJ 2012>

Save EUR420 per 9sqm!

For details, see exhibitor prospects

http://www.ics-expo.jp/biojapan/images/info_exhibitor/BJ_brochure_En.pdf

10

Organizer's seminars

Seminars will consist of Keynote speech, Sponsored Seminars, Exhibitor

Presentations, Academic Seeds Presentations and Global Partnering

Seminars. The followings were the major themes of 2012 Organizer’s seminar.

The details for 2013 to be announced.

・” Medicine and Pharmaceuticals” including ”Personalized medicine“

and “ Regenerative medicine”

・” Healthcare”

・” Food and the Agriculture and Fishery Industries ”

・” Environment and Energy”

・” The Foundation of Biotechnology-based Industry”

Seminars

11

Company Presentations

BioJapan 2013 invites exhibitors to present at the conference.

<Sponsored Seminar> <Exhibitor Presentation>

Seminars

Exhibitor Presentation in the exhibition hall (Venue: A presentation venue)

・For 9 sqm or more exhibitors： JPY262,500 (EUR2,100) per 30 minutes

・For 4 aqm exhibitors： JPY105,000 (EUR840) per 30 minutes

・For Academic Laboratories and TLO： JPY42,000 (EUR336) per 30 minutes

Sponsored Seminar in the Annex hall (Venue: A private room)

・Luncheon Seminar: JPY1,260,000 (EUR10,080) per 60 minutes

・Sponsored Seminar: JPY630,000 (EUR5,040) per 60 minutes

Note: The above cost does NOT include the simultaneous interpretation service.

Note: The above cost does NOT include the simultaneous interpretation service.

12

80

90

100

110

120

06 07 08 09 10 11

YEAR(JAN-DEC)

Business Opportunities in Japan

Company *Participated in the

BioJapan 2012 partnering

Sales

Figures

Operating

profits

R&D

Spender

Takeda* 18.40 3.23 3.43

Astellas Pharma* 11.82 1.60 2.31

Daiichi Sankyo* 11.44 1.19 2.25

Otsuka pharmaceutical* 9.53 2.05 1.82

Eisai* 7.90 1.16 1.52

Mitsubishi Tanabe Pharma* 4.96 0.84 0.85

Chugai pharmaceutical* 4.55 0.76 0.68

Dainippon Sumitomo Pharma* 4.27 0.24 0.69

Kyowa Hakko Kirin* 4.19 0.56 0.54

Taisho Pharmaceutical* 3.30 0.46 0.29

Japan is currently the second-largest pharmaceuticals market in the world

with growing demand for drugs due to high life expectancy and an aging

population. Total ethical drug sales in Japan based on

NHI price levels *Unit: Billion USD

Japanese TOP 10 pharmaceutical companies

based on FY2012 sales figures *Unit: Billion USD

Continued to grow

Source: MR Biz Source: IMS Japan

*1: Total ethical drug sales 2011 in Japan based on NHI price levels were approximately 115.6 billion USD.

*Based on exchange rates: USD1.00 = JPY 82.00

*2: Total R&D spender 2012 of Japanese top 10 pharmaceutical companies were approximately 14.38 billion USD.

*Based on exchange rates: USD1.00 = JPY82.00,

*1

*2

Market

13

(Summary) Japanese Outbound M&A deals

Japanese pharmaceutical companies become more global and

strengthen their pipelines by using M&A.

Market

Company Takeover candidate Deal Value US $ Date

Takeda (Japan) LigoCyte Pharmaceuticals, Inc. (US) 492 million Nov. 2012

Takeda (Japan) URL Pharma (US) 800 million Apr. 2012

Asahi Kasei (Japan) Zoll Medical (US) 2.21 billion Mar. 2012

Dainippon Sumitomo (Japan) Boston Biomedical Inc.(US) 200 million Feb. 2012

Takeda (Japan) Intellikine (US)190 million up front plus 120 million in

contingent milestonesDec. 2011

Fujifilm (Japan) SonoSite (US) 995 million Dec. 2011

Santen Pharma (Japan) Novagali (France) 135 million (50.55% of the shares) Oct. 2011

Takeda (Japan) Nycomed (Switzerland) 3.68 billion Sep. 2011

Astellas (Japan) and Maxygen (US) Perseid Therapeutics (US) 76 million May 2011

Takeda (Japan) Fate Therapeutics (US) Undisclosed ( Unspecified stake) May 2011

Kyowa Hakko Kirin (Japan) ProStrakan (UK) 474 million Apr. 2011

Daiichi Sankyo (Japan) Plexxikon (US) 805 million Apr. 2011

Nitto Denko (Japan) Avecia Biotech (US) Undisclosed Feb. 2011

Zeria pharmaceutical (Japan) Biofac Esbjerg A/S (Denmark) 12. 3 million (85% of the shares) Sep. 2010

KANEKA (Japan) Eurogentec(Belgium) 45 million Jul. 2010

Astellas (Japan) OSI Pharmaceuticals 4.00 billion Mar. 2010

Eisai (Japan) AkaRx (US) 255 million Jan. 2010

14

(Summary) Drug Discovery Collaboration Market

Japanese pharmaceutical companies are seeking partners in

order to accelerate drug development and make more efficient

use of precious capital.

It’s said that BioJapan is the best partnering event in Japan and

provides you a great opportunity to meet pharma professionals.

Company Partner Release date

Otsuka Pharmaceutical (JPN) Living Cell Technologies Limited (Australia) Dec. 2012

Takeda (JPN) Advinu (India) Oct. 2012

Ono Pharmaceutical (JPN) Domain Therapeutics S.A. (France) Oct. 2012

Takeda (JPN) The BC Cancer Agency (Canada) Aug, 2012

Daiichi Sankyo (JPN) NGM Biopharmaceuticals, Inc. (US) Mar. 2012

Teijin Pharma (JPN) NovAliX (France) Jan. 2012

Astellas (JPN) and Agensys, Inc. (US) Seattle Genetics, Inc.(US) Jun. 2011

Eisai(JPN) UCL (UK) May 2011

Takeda (JPN) Heptares Therapeutics (UK) Apr. 2011

Takeda (JPN) Samyang Corporation (S. Korea) Apr. 2011

Daiichi Sankyo (JPN) Pieris AG (Germany) Apr. 2011

Eisai(JPN) Epizyme, Inc.（US) Mar. 2011

Astellas (JPN) Cell Signaling Technology, Inc.(US) Feb. 2011

Ono Pharmaceutical (JPN) BioFocus(UK) Jan. 2011

Eisai(JPN) FORMA Therapeutics (US) Nov. 2010

Ono Pharmaceutical (JPN) BioSeek (US) Mar. 2010

15

Japanese Biotech IPOs

・Japanese Biotech IPOs in 2011 and 2012

・The number of Japanese biotech IPOs (yearly, 2008-2012)

Market

Hit a new record high in 2011 but many biotech companies will be forced to

shut down due to lack of funding.

Company Market IPO date

Eugrena Tokyo Stock Exchange Mothers Dec. 2012

UMN Pharma Tokyo Stock Exchange Mothers Dec. 2012

GENE TECHNO SCIENCE Tokyo Stock Exchange Mothers Nov. 2012

CHIOME Biosceiece Tokyo Stock Exchange Mothers Dec. 2011

SymBio Pharmaceutical Osaka Securities Exchange JASDAQ Growth Market Oct. 2011

3D Matrix Osaka Securities Exchange JASDAQ Growth Market Oct. 2011

RaQualia Pharma Osaka Securities Exchange JASDAQ Growth Market Jul. 2011

Mebiopharm Tokyo AIM Jul. 2011

16

Thank you for your interest in BioJapan

and I look forward to seeing you all in Japan.

CONTACT

Makoto Tanihara /

Global Event Manager

ADDRESS: Chiyoda Bldg., 1-5-18 Sarugaku-cho,

Chiyoda-ku, Tokyo 101-8449 Japan

PHONE: 03-3219-3565 / FAX: 03-3219-3628

E-mail: biojapan@ics-inc.co.jp

Website: http://www.icsexpo.jp/biojapan/en/index.html

17